The Marketed Market of Medicines

The session saw debate on the agenda, “Reviewing medical device regulations to strengthen policies of healthcare systems”, which ended with the aforementioned agenda being voted on and accepted. The committee then decided to move forward with the discussion of the topic, “Classification of medical device with regards to the agenda”.

The first speaker was the Delegate of Denmark who spoke at length about his country’s policies on the different types of classification of medical devices, including a statement of the change needed in ‘the degree of parameters’ and that the ideal method of classification must be one of a four tier system. Followed by the Delegate of the United Kingdom (UK) who again spoke on the guidelines for categorizing medical devices in the UK along with the specifications of a class three device and on the advantages and uses of pre-market approval that helps in the scrutinizing of the devices, where she made an error which was later corrected by another delegate, the correction being: “The UK follows class 1, 2A, 2B and 3” of their classification model.

The Delegate of China elucidated the need to classify these devices on the basis of their origin, describing how they could be separated into groups depending on the country they are sourced from. He further goes on to narrate that this is a necessary step to foster transparency and maintain detailed and traceable records. The Delegate of Iceland starts off by appreciating the ideas put forth by the Delegate of China and the Delegate of Denmark, explaining the techniques of his country and the Food and Drug Administration (FDA), ending his speech on an abrupt note due to lack of time. Further, The Delegate of France briefly recounted the roles of the FDA and illustrated the difference between the food and medical devices that are safe for human use and those that are not, calling it a “big distinction between food or drug that is FDA approved and those that are not”. He also said that the benefits of the food or drug far outweigh the side effects (if any) and requesting the member nations to take account of certain FDA green lit drugs that have not yet completed testing but are still available in the market for public use. The Delegate of France was accompanied by the delegates of other member countries, all of whom boldly presented their facts and statements in proving that their classification was far superior.